A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Issa Ismail Issa(Aalborg University Hospital), Karen Dybkær(Aalborg University Hospital), Rasmus Froberg Brøndum(Aarhus University), Linnéa Schmidt(Aalborg University Hospital), Hanne Due(Aalborg University Hospital), Martin Bøgsted(Chr. Hansen (Denmark))
Cancer Drug Resistance
January 1, 2020
10.20517/cdr.2020.76
Cited by 1

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
|Blood|2009|390
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Leukemia|2012|362
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247